PH80

About Vistagen Therapeutics

Vistagen Therapeutics is advancing a first-in-class pherine platform to develop fast-acting, non-addictive nasal sprays for major psychiatric disorders. Its lead candidate, fasedienol (PH94B), has demonstrated rapid-onset anxiolytic effects in Phase 3 trials for social anxiety disorder, positioning it as a potential breakthrough therapy. The company's strategy focuses on leveraging its novel, non-systemic mechanism to address high-unmet-need conditions while minimizing the drawbacks of conventional oral medications. Despite a challenging financial position and low market valuation, Vistagen's innovative approach represents a distinct and potentially disruptive opportunity in the neuropsychiatric space.

Therapeutic Areas